Tiziana Life Sciences Ltd

NASDAQ:TLSA

Biotechnology

Healthcare
$0.81 +2.78%

+$0.03 today

Market cap
$103.50M
Beta
0.42
P/E (TTM)
-4.0
EPS (TTM)
-$0.19
52W Low $1.04High $2.60

Volume 1.28M

Average 0.21M

TLSA Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Tiziana Life Sciences LtdNASDAQ: TLSA

Net Income · Q4 FY2025 · quarter ended Dec 2025

Net income grows 122.2% year over year

Q4 FY2025 net income of $12.8M (cash outflow) rose 122.2% year over year. Over 3 fiscal years it compounded at +13.7% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate of -$9.45M (-48.7%) for the fiscal year ending Dec 2026, a slowdown from the +94.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$12.8M— QoQ
Last fiscal yearDec 2025
-$18.43M+94.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+122.2%——
1 year+94.4%-48.7%-143.1 pp
3-year CAGR+13.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(18.43M) USD
Year-over-year change
-94.4%
Reported Analyst consensus estimate

Net Income vs competitors

How TLSA compares with its peers on the latest reported figures

  • TLSA's FY2025 net income of $18.43M is the 7th largest of the 9 companies compared; the peer median is $28.05M.
  • Its year-over-year change of +94.4% is the highest of 9, against a peer median of -10.7%.
  • Over three fiscal years its annual growth of +13.7% compares with a peer median of +7.6%.
TLSA Competitors Peer median
Net Income for TLSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$124.13M -44.6%-16.7%—
PLRXPliant Therapeutics, Inc.LTM Mar 2026$113.22M -48.4%+6.6%—
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M +26.1%-14.6%44.8%
IMMXImmix Biopharma, Inc.LTM Mar 2026$34.98M +67.3%+52.9%—
COYACoya Therapeutics, Inc.LTM Mar 2026$21.13M +23.3%+20.1%266.1%
WHWKWhitehawk Therapeutics IncLTM Dec 2025$20.6M -67.7%-30.2%288.3%
TLSATiziana Life Sciences LtdFY2025$18.43M +94.4%+13.7%—
EXOZeXoZymes, Inc.LTM Mar 2026$9.67M +44.2%+87.2%—
OKYOOKYO Pharma LimitedFY2025$7.97M -52.6%+8.6%—
Peer median (excluding TLSA) $28.05M-10.7%+7.6%266.1%

Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.36M)(12.55M)(14M)(9.48M)(18.43M)
Depreciation & Amortization104.52K41.57K75.97K99.09K234K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital(573.01K)(948.89K)(1.25M)(441.1K)3.06M
Accounts Receivables317.27K(127.17K)(1.14M)(1.11M)(692K)
Inventory00000
Accounts Payables00000
Other Working Capital(890.27K)(821.72K)(109.21K)670.44K3.75M
Other Non-Cash Items1.7M(2.53M)2.75M8.6M2.29M
Operating Cash Flow(16.13M)(15.99M)(12.42M)(1.22M)(12.85M)
Capital Expenditures(16.31K)00(15.18K)(21K)
Acquisitions (Net)00000
Purchases of Investments0(2.18M)(791.35K)(52K)0
Sales of Investments00000
Other Investing Activities112.67K(1.08M)(200.21K)10.45K3.06M
Investing Cash Flow96.37K(3.26M)(991.57K)(56.74K)3.04M
Debt Repayment000(141K)0
Common Stock Issued95.62K0125.83K3.71M10.2M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(112.67K)(44.84K)(94.17K)28.33K(196K)
Financing Cash Flow(17.05K)(44.84K)31.65K3.6M10.01M
Effect of Forex Changes(1.53M)(324.45K)(22.16K)(293.27K)84K
Net Change in Cash(17.59M)(19.62M)(13.4M)2.03M286K
Free Cash Flow(16.15M)(15.99M)(12.42M)(1.23M)(12.87M)

Tiziana Life Sciences Ltd

NASDAQ:TLSA

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.